2022 annual financial data
Estrella Immunopharma 2022 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -1,569,530 USD and net income was -996,104 USD.
Operating cash flow was -1,043,848 USD.
Get free Estrella Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -1,569,530 USD
- Net income
- -996,104 USD
- Operating cash flow
- -1,043,848 USD